Allogeneic stem cell transplantation for myelofibrosis in 2012.
Myelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identificatio...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826264412506292224 |
|---|---|
| author | McLornan, D Mead, A Jackson, G Harrison, C |
| author_facet | McLornan, D Mead, A Jackson, G Harrison, C |
| author_sort | McLornan, D |
| collection | OXFORD |
| description | Myelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identification of suitable candidates, timing of transplantation in the disease course and choice of conditioning regimen. This review summarizes key findings from published data concerning AHSCT in MF and attempts to provide a state of the art approach to MF-AHSCT in 2012. In addition, we postulate on how the era of JAK inhibition might impact on transplantation for MF. |
| first_indexed | 2024-03-06T20:07:22Z |
| format | Journal article |
| id | oxford-uuid:295a7253-a69a-43f2-bce5-37ccbe634bd0 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:07:22Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:295a7253-a69a-43f2-bce5-37ccbe634bd02022-03-26T12:18:38ZAllogeneic stem cell transplantation for myelofibrosis in 2012.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:295a7253-a69a-43f2-bce5-37ccbe634bd0EnglishSymplectic Elements at Oxford2012McLornan, DMead, AJackson, GHarrison, CMyelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identification of suitable candidates, timing of transplantation in the disease course and choice of conditioning regimen. This review summarizes key findings from published data concerning AHSCT in MF and attempts to provide a state of the art approach to MF-AHSCT in 2012. In addition, we postulate on how the era of JAK inhibition might impact on transplantation for MF. |
| spellingShingle | McLornan, D Mead, A Jackson, G Harrison, C Allogeneic stem cell transplantation for myelofibrosis in 2012. |
| title | Allogeneic stem cell transplantation for myelofibrosis in 2012. |
| title_full | Allogeneic stem cell transplantation for myelofibrosis in 2012. |
| title_fullStr | Allogeneic stem cell transplantation for myelofibrosis in 2012. |
| title_full_unstemmed | Allogeneic stem cell transplantation for myelofibrosis in 2012. |
| title_short | Allogeneic stem cell transplantation for myelofibrosis in 2012. |
| title_sort | allogeneic stem cell transplantation for myelofibrosis in 2012 |
| work_keys_str_mv | AT mclornand allogeneicstemcelltransplantationformyelofibrosisin2012 AT meada allogeneicstemcelltransplantationformyelofibrosisin2012 AT jacksong allogeneicstemcelltransplantationformyelofibrosisin2012 AT harrisonc allogeneicstemcelltransplantationformyelofibrosisin2012 |